Skip navigation

Using Advocacy to Increase Investment in Enteric Vaccine Development

Using Advocacy to Increase Investment in Enteric Vaccine Development

Author: 
Hope Randall
Laura Edison Kallen
Publication Date
Tuesday, February 5, 2019
Affiliation: 

PATH

Enterotoxigenic Escherichia coli (ETEC) and Shigella are among the leading bacterial causes of moderate-to-severe diarrhoea among children under 5 years of age. Yet, catalysing and sustaining momentum for long-term research investments can be a challenge. The workshop "Using advocacy to increase investment in enteric vaccine development" provided a forum at the July 2018 Vaccines Against Shigella and ETEC (VASE) Conference to build the capacity of scientists to communicate about their own research and advocate for additional attention and funding for enteric disease and vaccines research. Workshop presenters shared best practices and examples of advocacy, communications, and messaging tactics that have been used during early stages of vaccine development research for other pathogens. The presentations were followed by an interactive, hands-on training for real-life communication opportunities for scientists, including a review of media interview best practices.

  <div class="field button"><a href="https://www.sciencedirect.com/science/article/pii/S0264410X18317067" 0="s:6:&quot;a:0:{}&quot;;" target="_blank">Click here to read the article online or to download it in PDF format (3 pages).</a></div>
Contacts (user reference): 
Source: 

Vaccine https://doi.org/10.1016/j.vaccine.2018.12.033. Image credit: PATH

read more

The Media Development Network